The state Supreme Court has denied a group of drugmakers’ request that the Superior Court be ordered to hear their discretionary appeals on the issue of whether federal law pre-empts the claims of at least 2,000 plaintiffs that their use of generic versions of metoclopramide caused them to have an incurable neurological disorder called tardive dyskinesia.

But the frontline appeals court is scheduled to consider whether the cases may be taken up under the collateral order doctrine. The cases are listed to be argued on October 30 or 31.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at customercare@alm.com